A carregar...
The Dual Blockade in the Neoadjuvant Setting of HER-2 Positive Early-Stage Breast Cancer
Patients with positive Her-2/neu breast cancer and a high risk of recurrence are known to benefit from the addition of the dual blockade of Her-2/neu with Trastuzumab and Pertuzumab to the neoadjuvant chemotherapy, a combination which has been demonstrated to give a higher rate of a complete patholo...
Na minha lista:
| Publicado no: | J Med Life |
|---|---|
| Main Authors: | , , , , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
Carol Davila University Press
2019
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6993292/ https://ncbi.nlm.nih.gov/pubmed/32025249 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.25122/jml-2019-0115 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|